

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Leslie P. Weiner et al.
APPLICATION NO.: 10/773,356
FILING DATE: February 5, 2004
TITLE: T-Cell Vaccination for the Treatment of Multiple Sclerosis
EXAMINER: Gerald R. Ewoldt
GROUP ART UNIT: 1644
ATTY. DKT. NO.: 23714-07992/US

CERTIFICATE OF ELECTRONIC (EFS-WEB) TRANSMISSION

I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with 37 C.F.R. § 1.8(a)(i)(C) from the Pacific Time Zone of the United States on the local date shown below.

Dated: October 18, 2007

By: /Susan T. Hubl/
Susan T. Hubl,

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
Under 37 CFR §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 CFR §§ 1.56 and 1.97-98, enclosed herewith is modified form PTO/SB/08A listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

- ☒ after three months of the filing date of this national application or the date of entry of the national stage in an international application, or after the mailing date of the first official action on the merits, whichever event last occurred, but before the mailing date of the first to occur of either: (1) a

final action under 37 CFR §1.113; or (2) an action that otherwise closes prosecution in the application, and:

- ☒ Applicant certifies pursuant to 37 CFR § 1.97(e) that:
 - ☒ each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☒ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 CFR § 1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement. 37 CFR § 1.704(d).
- ☒ Copies of any foreign patent documents and non-patent literature cited herein are enclosed.

Consideration of the listed references and favorable action are solicited.

Respectfully submitted,
LESLIE P. WEINER ET AL.

Dated: October 18, 2007

By /Susan T. Hubl/
Susan T. Hubl, Ph.D., Patent Agent
Reg. No.: 47,668
Fenwick & West LLP
Silicon Valley Center
801 California Street
Mountain View, CA 94041
Tel.: (415) 875-2316
Fax.: (650) 938-5200